BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 30634629)

  • 1. High
    Xie L; Dang Y; Guo J; Sun X; Xie T; Zhang L; Yan Z; Amin H; Guo X
    Genes (Basel); 2019 Jan; 10(1):. PubMed ID: 30634629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma.
    Xu XL; Gong Y; Zhao DP
    Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8731-8739. PubMed ID: 30575913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased GOLM1 Expression Independently Predicts Unfavorable Overall Survival and Recurrence-Free Survival in Lung Adenocarcinoma.
    Liu X; Chen L; Zhang T
    Cancer Control; 2018; 25(1):1073274818778001. PubMed ID: 29843532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KRT8 and KRT19, associated with EMT, are hypomethylated and overexpressed in lung adenocarcinoma and link to unfavorable prognosis.
    Wang W; He J; Lu H; Kong Q; Lin S
    Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32519739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of KIF18A promotes cell proliferation, inhibits apoptosis, and independently predicts unfavorable prognosis in lung adenocarcinoma.
    Zhong Y; Jiang L; Lin H; Li X; Long X; Zhou Y; Li B; Li Z
    IUBMB Life; 2019 Jul; 71(7):942-955. PubMed ID: 30817091
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Hou L; Li Y; Wang Y; Xu D; Cui H; Xu X; Cong Y; Yu C
    Dis Markers; 2018; 2018():4108919. PubMed ID: 30420903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant S100A16 expression might be an independent prognostic indicator of unfavorable survival in non-small cell lung adenocarcinoma.
    Chen D; Luo L; Liang C
    PLoS One; 2018; 13(5):e0197402. PubMed ID: 29746588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High ECT2 expression is an independent prognostic factor for poor overall survival and recurrence-free survival in non-small cell lung adenocarcinoma.
    Zhou S; Wang P; Su X; Chen J; Chen H; Yang H; Fang A; Xie L; Yao Y; Yang J
    PLoS One; 2017; 12(10):e0187356. PubMed ID: 29088286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of CEP55 gene as a diagnostic biomarker and independent prognostic factor in LUAD and LUSC.
    Fu L; Wang H; Wei D; Wang B; Zhang C; Zhu T; Ma Z; Li Z; Wu Y; Yu G
    PLoS One; 2020; 15(5):e0233283. PubMed ID: 32437446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of SUMO1P3 Compared with SUMO1 is an Independent Predictor of Patient Outcome in Lung Adenocarcinoma.
    Su X; Wan Y; Xie L; Lin X; Zhao H; Ju X; Fang A
    Med Sci Monit; 2019 Sep; 25():6691-6701. PubMed ID: 31489957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. USP4 expression independently predicts favorable survival in lung adenocarcinoma.
    Zhong M; Jiang Q; Jin R
    IUBMB Life; 2018 Jul; 70(7):670-677. PubMed ID: 29667299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LDHA upregulation independently predicts poor survival in lung adenocarcinoma, but not in lung squamous cell carcinoma.
    Yu C; Hou L; Cui H; Zhang L; Tan X; Leng X; Li Y
    Future Oncol; 2018 Oct; 14(24):2483-2492. PubMed ID: 29756998
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Zhang W; Li T; Hu B; Li H
    Technol Cancer Res Treat; 2020; 19():1533033820957030. PubMed ID: 33084541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring and comparing of the gene expression and methylation differences between lung adenocarcinoma and squamous cell carcinoma.
    Yang Y; Wang M; Liu B
    J Cell Physiol; 2019 Apr; 234(4):4454-4459. PubMed ID: 30317601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. System analysis of
    Situ Y; Gao R; Lei L; Deng L; Xu Q; Shao Z
    Int J Biol Markers; 2022 Jun; 37(2):158-169. PubMed ID: 35254116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrative bioinformatics analysis the clinical value of KMT5A in different subtypes of lung cancer.
    Liu S; Tian W; Li B
    Comput Biol Chem; 2022 Feb; 96():107603. PubMed ID: 34894606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The High Expression of PTPRH Is Associated with Poor Prognosis of Human Lung Adenocarcinoma.
    Chen A; Ding S; Shen X; Lin X
    Comput Math Methods Med; 2021; 2021():9932088. PubMed ID: 34367321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The genomic alterations of lung adenocarcinoma and lung squamous cell carcinoma can explain the differences of their overall survival rates.
    Meng F; Zhang L; Ren Y; Ma Q
    J Cell Physiol; 2019 Jul; 234(7):10918-10925. PubMed ID: 30549039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of Family with Sequence Similarity 83, Member A (FAM83A) Predicts Poor Clinical Outcomes in Lung Adenocarcinoma.
    Zhang JT; Lin YC; Xiao BF; Yu BT
    Med Sci Monit; 2019 Jun; 25():4264-4272. PubMed ID: 31175804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic alternative mRNA splicing signature in non-small cell lung cancer.
    Li Y; Sun N; Lu Z; Sun S; Huang J; Chen Z; He J
    Cancer Lett; 2017 May; 393():40-51. PubMed ID: 28223168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.